Justin S. Waters

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan et al. · The Lancet Oncology · 2021 · 749 citations · Full text

Medicine, Oncology, Pharmacology +8

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Ian Chau, David Cunningham, David González de Castro et al. · The Lancet Oncology · 2013 · 728 citations

Medicine, Oncology, Pharmacology +13

Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data

Ian Chau, Andy Norman, David Cunningham et al. · Journal of Clinical Oncology · 2004 · 531 citations

Medicine, Oncology, Chemotherapy +14

Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

Paul J. Ross, S. Ashley, A. Norton et al. · British Journal of Cancer · 2004 · 477 citations · Full text

Medicine, Oncology, Chemotherapy +13

Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma

Justin S. Waters, Andrew Webb, David Cunningham et al. · Journal of Clinical Oncology · 2000 · 456 citations

Medicine, Oncology, Pharmacology +13